<DOC>
	<DOC>NCT01609556</DOC>
	<brief_summary>The purpose of this study is to test IMGN853 in patients with FOLR-1 positive tumors.</brief_summary>
	<brief_title>First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Criteria for Selection of Patient Population Inclusion Criteria Patients with advanced solid tumor that is refractory to standard treatment, for which no standard treatment is available, or the patient refuses standard therapy. â‰¥ 18 years old at the time of informed consent. ECOG Performance Status 0 or 1. Patients must have adequate hematologic and organ function. Patients must be willing and able to sign the informed consent form, and to follow the study visit schedule and other protocol requirements. Women of childbearing potential and men must agree to use effective contraceptive methods while on study and for at least twelve weeks after the last dose of study drug. Women of childbearing potential must have a negative pregnancy test prior to the first dose of study treatment. Exclusion Criteria Grade &gt;1 neuropathy Any active or chronic corneal disorder and Sjogren's syndrome. Serious concurrent illness: Any other concomitant anticancer treatment. Women of childbearing potential who are pregnant or breast feeding.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>FOLR solid tumors</keyword>
</DOC>